Electrical microcurrent as a curative approach
Berlin Heals has developed a novel implantable electroceutical device, called «C-MIC»: A small implantable device that propagates reverse remodeling of the cardiac muscle tissue by delivering a constant but minimal electrical direct current (DC) equivalent to physiological electrical currents in the heart.
The reason why
As of today, no other medical device, drug or therapy has been developed that is able to reverse heart failure
To remedy this shortcoming, Berlin Heals was incorporated in 2014 with the mission to establish a novel therapeutic approach to not only delay the progression of heart failure disease but to virtually cure it.
C-MIC Device Functionality
The C-MIC is a small implantable device that propagates reverse remodeling of the cardiac muscle tissue
Our approach was, has been, and still is to treat heart failure by using electrical microcurrent to drive out excess edema from the heart cells by applying an electric field (electroosmosis) and then in parallel inducing a progression from reverse modeling to true myocardial recovery.
On this premise, Berlin Heals has developed a novel implantable electroceutical device, the “Cardiac Microcurrent Therapy Device” or C-MIC. The C-MIC is a small implantable device that propagates reverse remodeling of the cardiac muscle tissue by delivering a constant but minimal electrical direct current (DC) equivalent to physiological microcurrents to the heart via two leads/electrodes, one placed on the epicardium of the left ventricle and the other in the right ventricular cavity.
The C-MIC device is a patented novel technology owned by Berlin Heals Holding Ltd., Zug (Switzerland).
Scientific Background
The technological principles underlying the C-MIC are the results of extensive pre-clinical trials
The trials were designed and run by Berlin Heals in close scientific cooperation et al. with the Medical University of Vienna, which confirmed that microcurrents have an extremely positive effect (regenerative and anti-inflammatory) on cardiac cells. Link to Scientific Paper
Based on this research, the company developed and widely tested its proprietary C-MIC device first in animals (sheep), leading to very successful trial results. Following these promising results, Berlin Heals proceeded to test its technology in human patients (implantations under study conditions).
Promising Studies
Promising Results in
First-in-human Studies
Dual Center First-in-human Studies (2019/2020) & Launch of EU and US Studies (2021/2023): Berlin Heals successfully completed a pilot study (dual center First-in-human studies in Belgrade, Serbia and Vienna Austria) with 10 patients suffering from a condition called “dilative cardiomyopathy” in April 2020.
